SHARE

Isomorphic Labs to trial AI-developed drug by end of year

The drug discovery startup, which is owned by Alphabet, has said that it is looking at oncology, cardiovascular and neurodegeneration for its drug development, and expects to have an AI-designed medication in trials by the end of the year.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.